J&J pays $3.4 billion for robotics firm AurisJohnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that Share XJ&J pays $3.4 billion for robotics firm Aurishttps://pharmaphorum.com/news/jj-pays-robotics-firm-auris/
Clinigen buys remaining rights to Novartis cancer drugUK pharma Clinigen has bought the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up Share XClinigen buys remaining rights to Novartis cancer drughttps://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/
Mylan launches Advair generic at 70% discount in USMylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the Share XMylan launches Advair generic at 70% discount in UShttps://pharmaphorum.com/news/mylan-launches-advair-generic-at-70-discount-in-us/
FDA panel backs J&J’s potential depression blockbusterA panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal Share XFDA panel backs J&J’s potential depression blockbusterhttps://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
Sanofi appoints its first chief digital officerSanofi has become the latest big pharma firm to appoint a chief digital officer, choosing Ameet Nathwani to Share XSanofi appoints its first chief digital officerhttps://pharmaphorum.com/news/sanofi-appoints-its-first-chief-digital-officer/
Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
Catalyst sparks price row in US with $300,000 rare disease drugThe controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share XCatalyst sparks price row in US with $300,000 rare disease drughttps://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
NHS should invest in digital, AI, and robotics trainingThe Topol Review of the training needs of the future NHS workforce has published its recommendations – including Share XNHS should invest in digital, AI, and robotics traininghttps://pharmaphorum.com/news/nhs-should-invest-in-digital-ai-and-robotics-training/
